Global Progressive Supranuclear Palsy (PSP) Treatment Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Progressive Supranuclear Palsy (PSP) Treatment Market Segmentation, By Drug Type (Dopamine, Anticholinergic Agents, Tricyclic Antidepressants, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Pharmacies)- Industry Trends and Forecast to 2032

Progressive Supranuclear Palsy (PSP) Treatment Market Size

• The global Progressive Supranuclear Palsy (PSP) Treatment market size was valued at USD 16.00 million in 2024 and is expected to reach USD 24.55 million by 2032, at a CAGR of 5.50% during the forecast period
• The market growth is largely fueled by the increasing prevalence of neurodegenerative disorders, a rising geriatric population, and growing investments in research and development for novel PSP therapies, leading to greater awareness and earlier diagnosis
• Furthermore, advancements in diagnostics, emerging disease-modifying therapies, and heightened patient demand for effective treatment solutions are establishing PSP treatments as a critical component of neurodegenerative care. These converging factors are accelerating the adoption of PSP therapies, thereby significantly boosting the industry's growth

Progressive Supranuclear Palsy (PSP) Treatment Market Analysis

• PSP treatments, including dopamine, anticholinergic agents, tricyclic antidepressants, and other therapies, are increasingly vital components of neurodegenerative disorder management due to their potential to improve patient quality of life, manage disease progression, and address motor and cognitive symptoms effectively
• The escalating demand for PSP treatments is primarily fueled by the rising prevalence of neurodegenerative disorders, an aging global population, and growing awareness among healthcare providers and patients about early diagnosis and intervention
• North America dominated the PSP treatment market with the largest revenue share of 40% in 2024, characterized by advanced healthcare infrastructure, high healthcare spending, and a strong presence of key pharmaceutical companies, with the U.S. experiencing substantial growth in PSP therapy adoption, driven by ongoing clinical trials and innovations in disease-modifying treatments
• Asia-Pacific is expected to be the fastest growing region in the PSP treatment market during the forecast period due to increasing healthcare access, rising disposable incomes, and expanding neurological care infrastructure
• Dopamine segment dominated the PSP treatment market with a market share of 42.5% in 2024, driven by its established role in improving motor function and overall symptom management

Report Scope and Progressive Supranuclear Palsy (PSP) Treatment Market Segmentation  

Progressive Supranuclear Palsy (PSP) Treatment Market Trends

Advancements in Targeted Therapies and Personalized Medicine

• A significant and accelerating trend in the global PSP treatment market is the increasing development of targeted therapies and personalized treatment plans based on patient-specific biomarkers, improving efficacy and patient outcomes

  • For instance, research by Axovant Sciences focuses on gene-targeted therapies to modulate disease progression in PSP patients, aiming to provide precision treatment options

• Integration of personalized medicine approaches in PSP treatment enables clinicians to tailor therapeutic interventions based on symptom profile, disease stage, and genetic factors, enhancing overall treatment effectiveness
• Combination therapies involving dopamine, anticholinergic agents, and supportive pharmacological interventions are being explored to address both motor and cognitive symptoms, providing a more comprehensive patient management approach
• This trend towards precision therapies and tailored treatment regimens is fundamentally reshaping clinical expectations for PSP management, as companies such as Biohaven and Avexis develop novel agents targeting underlying disease mechanisms
• The demand for advanced PSP therapies with personalized and targeted approaches is growing rapidly across both clinical and research settings, as healthcare providers increasingly prioritize efficacy and patient-centered outcomes

Progressive Supranuclear Palsy (PSP) Treatment Market Dynamics

Driver

“Rising Prevalence of Neurodegenerative Disorders and Geriatric Population

• The increasing prevalence of PSP and other neurodegenerative disorders, coupled with the growing aging population, is a significant driver for heightened demand for effective PSP treatments

  • For instance, a 2024 report by the National Institute of Neurological Disorders and Stroke highlighted the growing number of diagnosed PSP cases globally, emphasizing early intervention needs

• As awareness of PSP symptoms and disease progression rises, healthcare providers and patients seek therapies that manage motor dysfunction, cognitive impairment, and behavioral issues effectively
• Furthermore, investments in research and development, including clinical trials for disease-modifying agents, are expanding treatment options and increasing adoption rates among neurologists and specialized centers
• Patient demand for therapies that improve quality of life, reduce symptom burden, and integrate into comprehensive care plans is further propelling market growth

Restraint/Challenge

Limited Disease-Modifying Treatments and High Therapy Costs

• Concerns surrounding the lack of approved disease-modifying treatments for PSP pose a significant challenge to broader market adoption and patient outcomes

  • For instance, high-profile clinical trial failures for certain neuroprotective agents have made some physicians cautious in prescribing emerging therapies for PSP management

• Addressing unmet medical needs through continued R&D, supportive therapies, and symptom management protocols is crucial to building clinician and patient trust in PSP treatments
• In addition, the relatively high cost of advanced PSP therapies compared to conventional symptomatic treatments can be a barrier to adoption for healthcare systems and patients, particularly in developing regions
• Overcoming these challenges through affordable treatment options, enhanced physician awareness, and improved patient support programs will be vital for sustained market growth

Progressive Supranuclear Palsy (PSP) Treatment Market Scope

The market is segmented on the basis of drug type and distribution channel.

• By Drug Type

On the basis of drug type, the PSP treatment market is segmented into dopamine, anticholinergic agents, tricyclic antidepressants, and others. The dopamine segment dominated the market with the largest market revenue share of 42.5% in 2024, driven by its established efficacy in improving motor function and mitigating rigidity and bradykinesia in PSP patients. Clinicians often prioritize dopamine therapies due to their rapid impact on mobility and daily functioning. The market also sees strong demand for dopamine treatments because of their compatibility with adjunctive symptomatic therapies and established dosing protocols. Patient adherence is higher for dopamine therapies due to noticeable clinical effects, reinforcing their dominance in the treatment landscape. Dopamine treatments are widely prescribed across hospitals and specialized neurological clinics, making them the backbone of PSP pharmacotherapy.

The anticholinergic agents segment is anticipated to witness the fastest growth rate of 18.5% from 2025 to 2033, fueled by increasing adoption for managing PSP-related tremors, dystonia, and cognitive symptoms. These therapies provide supplementary symptom relief alongside dopamine treatments, enabling a comprehensive management approach. The growing pipeline of next-generation anticholinergic drugs with improved safety profiles is expected to drive higher uptake. Adoption is rising in regions with expanding neurological care infrastructure and increasing awareness of PSP. Oral formulations and predictable pharmacokinetics further support market growth. Ongoing clinical research exploring cognitive and behavioral benefits also contributes to the accelerated expansion of this segment.

• By Distribution Channel

On the basis of distribution channel, the PSP treatment market is segmented into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. The hospital pharmacies segment dominated the market with the largest revenue share of 46% in 2024, driven by direct physician prescriptions and patient access to advanced neurological care. Hospital pharmacies are preferred for dopamine and anticholinergic agents due to controlled dispensing and integration into clinical treatment plans. Patients often receive initial therapies, follow-ups, and monitoring through hospital channels. Hospitals also provide education and counseling on PSP medication management, enhancing adherence. The segment’s dominance is reinforced by the high concentration of specialized neurology centers in North America and Europe.

The online pharmacies segment is anticipated to witness the fastest growth rate of 20.3% from 2025 to 2033, fueled by increasing e-commerce adoption and rising demand for home delivery of PSP therapies. Online pharmacies provide convenience, especially for elderly or mobility-limited patients, and ensure access to medications in remote regions. Integration with digital health platforms enables automated prescription management and timely refills. The growing popularity of telemedicine consultations also supports online pharmacy adoption. Affordability, subscription models, and discreet delivery further enhance patient preference. Online channels are expected to expand rapidly, particularly in Asia-Pacific and North America, due to increasing digital healthcare infrastructure.

Progressive Supranuclear Palsy (PSP) Treatment Market Regional Analysis

• North America dominated the PSP treatment market with the largest revenue share of 40% in 2024, characterized by advanced healthcare infrastructure, high healthcare spending, and a strong presence of key pharmaceutical companies, with the U.S. experiencing substantial growth in PSP therapy adoption, driven by ongoing clinical trials and innovations in disease-modifying treatments
• Patients and clinicians in the region highly value the accessibility of specialized neurological care, comprehensive treatment options, and integration of advanced therapies such as dopamine and anticholinergic agents into clinical practice
• This widespread adoption is further supported by ongoing clinical trials, strong R&D investments by pharmaceutical companies, and increasing government initiatives to improve neurodegenerative disease management, establishing PSP treatments as a preferred choice in both hospital and retail pharmacy channels

U.S. Progressive Supranuclear Palsy (PSP) Treatment Market Insight

The U.S. PSP treatment market captured the largest revenue share of 42% in 2024 within North America, fueled by a high prevalence of neurodegenerative disorders and advanced healthcare infrastructure. Patients and clinicians are increasingly prioritizing access to effective therapies, including dopamine and anticholinergic agents, for improved symptom management. The growing trend of early diagnosis, coupled with strong R&D investments in novel PSP therapies, further propels market growth. Moreover, the integration of hospital pharmacies, specialized neurology centers, and online pharmacy channels is significantly contributing to the market’s expansion. The availability of clinical trials and supportive care programs also enhances patient adherence and therapy adoption.

Europe Progressive Supranuclear Palsy (PSP) Treatment Market Insight

The Europe PSP treatment market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by rising awareness of neurodegenerative disorders and increased healthcare spending. The increase in specialized neurological centers, coupled with the demand for effective pharmacological therapies, is fostering market adoption. European patients and healthcare providers are drawn to comprehensive treatment plans that combine dopamine, anticholinergic agents, and supportive therapies. The region is experiencing significant growth across hospital and retail pharmacy channels, with PSP therapies being incorporated into both early diagnosis programs and long-term care plans. Strong reimbursement frameworks and clinical guideline support further stimulate market expansion.

U.K. Progressive Supranuclear Palsy (PSP) Treatment Market Insight

The U.K. PSP treatment market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing awareness of PSP symptoms and the demand for improved patient quality of life. In addition, healthcare providers are emphasizing early intervention and multidisciplinary care, encouraging adoption of approved pharmacological therapies. The U.K.’s robust hospital infrastructure and integrated pharmacy network are expected to continue facilitating access to PSP treatments. Patient support programs and clinical research initiatives further contribute to market growth. Awareness campaigns and collaboration between healthcare institutions and pharmaceutical companies also play a significant role in stimulating adoption.

Germany Progressive Supranuclear Palsy (PSP) Treatment Market Insight

The Germany PSP treatment market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing investments in neurological research and the growing need for effective symptom management. Germany’s advanced healthcare infrastructure, emphasis on innovation, and strong presence of pharmaceutical companies promote the adoption of PSP therapies, particularly in hospital and retail pharmacy channels. Integration of patient monitoring programs and adherence support initiatives enhances treatment outcomes. The market also benefits from awareness programs emphasizing early diagnosis and the benefits of targeted therapies. Growth is particularly strong in urban centers with access to specialized neurology clinics.

Asia-Pacific Progressive Supranuclear Palsy (PSP) Treatment Market Insight

The Asia-Pacific PSP treatment market is poised to grow at the fastest CAGR of 19% during the forecast period of 2025 to 2033, driven by increasing healthcare access, rising disposable incomes, and growing awareness of neurodegenerative disorders in countries such as China, Japan, and India. The region’s expanding network of hospitals, clinics, and pharmacies is driving adoption of dopamine and anticholinergic therapies. Government initiatives promoting neurological healthcare and digital health solutions are further supporting market growth. In addition, as APAC emerges as a hub for clinical trials and R&D in neurodegenerative disorders, affordability and accessibility of PSP therapies are improving. The availability of patient support programs and educational initiatives is expanding awareness and therapy uptake across both urban and semi-urban populations.

Japan Progressive Supranuclear Palsy (PSP) Treatment Market Insight

The Japan PSP treatment market is gaining momentum due to the country’s aging population, high healthcare standards, and demand for advanced treatment options. The Japanese market places significant emphasis on early diagnosis and management of neurodegenerative disorders, driving adoption of dopamine and anticholinergic therapies. Integration with hospital pharmacies, specialized neurology centers, and telemedicine services supports efficient patient access. Patient adherence programs and clinical research initiatives further stimulate market growth. The prevalence of supportive care services, combined with innovative therapy options, enhances treatment outcomes. Growing public awareness campaigns regarding PSP symptoms are also driving therapy adoption.

India Progressive Supranuclear Palsy (PSP) Treatment Market Insight

The India PSP treatment market accounted for the largest market revenue share in Asia-Pacific in 2024, attributed to the country’s expanding healthcare infrastructure, rising awareness of neurological disorders, and growing availability of advanced pharmacological therapies. India stands as a rapidly emerging market for PSP treatments, with adoption in hospital and retail pharmacies increasing steadily. Government initiatives promoting neurological healthcare, combined with digital health solutions and telemedicine integration, are driving patient access. The availability of affordable therapies, supportive care programs, and growing physician awareness are key factors propelling market growth in India. Rising disposable incomes and urbanization further support therapy adoption.

Progressive Supranuclear Palsy (PSP) Treatment Market Share

The Progressive Supranuclear Palsy (PSP) Treatment industry is primarily led by well-established companies, including:

• Grupo Ferrer Internacional, S.A. (Spain)
• Asceneuron (Switzerland)
• AMYLYX Pharmaceuticals, (U.S.)
• Alzprotect (France)
• CurePSP, Inc., (U.S.)
• Acorda Therapeutics, Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Retrotope, Inc. (U.S.)
• Sumitomo Pharma Co., Ltd. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Charles River Laboratories (U.S.)
• Biogen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Cleveland Clinic (U.S.)
• Mayo Clinic (U.S.)
• Paris Brain Institute (France)

What are the Recent Developments in Global Progressive Supranuclear Palsy (PSP) Treatment Market?

• In August 2025, Amylyx Pharmaceuticals announced the discontinuation of its experimental drug AMX0035 for PSP after it failed to show improvement over a placebo in a mid-stage clinical trial. This decision underscores the challenges in developing effective treatments for PSP and highlights the need for continued research in this area
• In June 2025, Ferrer announced that the U.S. FDA granted Fast Track designation to FNP-223, a novel therapy aimed at slowing the progression of PSP. This designation facilitates expedited development and review processes, potentially accelerating the availability of FNP-223 for PSP patients
• In March 2025, Charles Garcia's research focused on recreating the precise tau protein aggregates found in PSP and CBD to improve drug development. Unsuch as current methods that use artificial tau structures, this project aims to induce tau aggregation using fatty acids, known to undergo oxidation in PSP, to generate biologically relevant formations
• In February 2025, CurePSP launched a groundbreaking Genetics Program aimed at addressing knowledge gaps in PSP, corticobasal degeneration (CBD), and multiple system atrophy (MSA) research. This initiative seeks to enhance understanding of the genetic underpinnings of these neurodegenerative disorders, potentially informing future therapeutic strategies
• In September 2024, the University of California, San Francisco (UCSF) initiated a platform trial to evaluate the safety and efficacy of multiple drugs for PSP. This innovative trial design allows for the simultaneous testing of various therapies, potentially streamlining the development of effective treatments for PSP

SKU-60819